Bellevue Group AG Increases Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Bellevue Group AG boosted its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 26.3% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 7,200 shares of the company’s stock after acquiring an additional 1,500 shares during the quarter. Bellevue Group AG’s holdings in IDEAYA Biosciences were worth $228,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Allworth Financial LP grew its position in shares of IDEAYA Biosciences by 800.0% in the third quarter. Allworth Financial LP now owns 900 shares of the company’s stock valued at $29,000 after purchasing an additional 800 shares during the period. Covestor Ltd lifted its stake in IDEAYA Biosciences by 23,050.0% in the 3rd quarter. Covestor Ltd now owns 926 shares of the company’s stock valued at $29,000 after buying an additional 922 shares in the last quarter. Quest Partners LLC acquired a new stake in IDEAYA Biosciences in the 2nd quarter worth about $41,000. Comerica Bank increased its stake in IDEAYA Biosciences by 723.5% during the 1st quarter. Comerica Bank now owns 1,507 shares of the company’s stock worth $66,000 after buying an additional 1,324 shares in the last quarter. Finally, US Bancorp DE raised its holdings in shares of IDEAYA Biosciences by 67.2% during the third quarter. US Bancorp DE now owns 1,714 shares of the company’s stock valued at $54,000 after acquiring an additional 689 shares during the last quarter. Hedge funds and other institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Stock Performance

IDYA opened at $27.36 on Monday. The stock has a market capitalization of $2.36 billion, a PE ratio of -11.74 and a beta of 0.86. IDEAYA Biosciences, Inc. has a one year low of $25.20 and a one year high of $47.74. The business’s 50 day moving average price is $29.53 and its 200 day moving average price is $35.23.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its earnings results on Monday, November 4th. The company reported ($0.60) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.03. During the same period in the previous year, the company posted ($0.46) earnings per share. As a group, equities research analysts forecast that IDEAYA Biosciences, Inc. will post -2.46 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on IDYA shares. Citigroup lowered their price target on IDEAYA Biosciences from $60.00 to $58.00 and set a “buy” rating on the stock in a research note on Tuesday, August 27th. Cantor Fitzgerald initiated coverage on shares of IDEAYA Biosciences in a report on Tuesday, October 15th. They set an “overweight” rating for the company. Leerink Partners cut shares of IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $41.00 to $27.00 in a research report on Tuesday, November 5th. UBS Group initiated coverage on shares of IDEAYA Biosciences in a research report on Thursday, October 24th. They set a “buy” rating and a $50.00 price target on the stock. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $53.00 price objective on shares of IDEAYA Biosciences in a research note on Tuesday, October 29th. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $53.67.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.